Copyright, Intellectual Property, Patents, Trade marks IPO 2018: Insights from the USPTO, EPO and the bench (when digital natives meet digital immigrants) 28 September 2018 By Suzy Madar Read on
Intellectual Property, Patents United States FDA gets serious about biosimilars 5 September 2018 By Suzy Madar Read on
Intellectual Property, Patents Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China 27 April 2018 By Suzy Madar Read on
Intellectual Property, Patents Second throw of the dice unsuccessful: Full Federal Court confirms Hepatitis C drug patent is invalid 21 December 2017 By Suzy Madar Read on
Intellectual Property Biosimilars: balancing access to affordable medicines with safety 3 November 2017 By Suzy Madar Read on
Intellectual Property, Patents Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent) 26 August 2016 By Suzy Madar Read on
Intellectual Property Next steps after Australia China Free Trade Agreement – how to make the most of the opportunity 23 July 2015 By Suzy Madar Read on
Copyright, Designs, Intellectual Property, Patents, Trade marks Australia signs Free Trade Agreement with China – important implications for IP owners and healthcare providers 22 June 2015 By Suzy Madar Read on
Intellectual Property, Patents Court rejects ACCC claim against Pfizer 25 February 2015 By Suzy Madar Read on